Status:
COMPLETED
The STAR Prospective Clinical Series
Lead Sponsor:
DFINE Inc.
Conditions:
Metastasis to Vertebral Column
Eligibility:
All Genders
18-100 years
Brief Summary
Prospective clinical series to gather post tumor ablation clinical outcomes from subjects with painful spinal metastases following targeted radiofrequency ablation (t-RFA) treatment with the STAR™ Tum...
Eligibility Criteria
Inclusion
- The STAR™ Tumor Ablation System is indicated for palliative treatment in spinal procedures by ablation of metastatic malignant lesions in a vertebral body.
Exclusion
- The device is contraindicated in subjects with heart pacemakers, or other electronic device implants.
- The device is contraindicated in vertebral body levels C1-7.
Key Trial Info
Start Date :
June 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2016
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT02217150
Start Date
June 1 2013
End Date
April 1 2016
Last Update
January 20 2017
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Palomar Pomerado Health System
Escondido, California, United States, 92027
2
University of Southern California
Los Angeles, California, United States, 90033
3
University of Kansas Medical Center
Kansas City, Kansas, United States, 66160
4
Suburban Hospital
Bethesda, Maryland, United States, 20814